AU740694B2 - Preparation having increased in vivo tolerability - Google Patents

Preparation having increased in vivo tolerability Download PDF

Info

Publication number
AU740694B2
AU740694B2 AU66005/98A AU6600598A AU740694B2 AU 740694 B2 AU740694 B2 AU 740694B2 AU 66005/98 A AU66005/98 A AU 66005/98A AU 6600598 A AU6600598 A AU 6600598A AU 740694 B2 AU740694 B2 AU 740694B2
Authority
AU
Australia
Prior art keywords
compound
acid
preparation
active compound
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU66005/98A
Other languages
English (en)
Other versions
AU6600598A (en
Inventor
Matthias Blumrich
Klaus Bosslet
Jorg Czech
Manfred Gerken
Rainer Straub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU6600598A publication Critical patent/AU6600598A/en
Application granted granted Critical
Publication of AU740694B2 publication Critical patent/AU740694B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU66005/98A 1997-05-15 1998-05-15 Preparation having increased in vivo tolerability Ceased AU740694B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19720312 1997-05-15
DE19720312A DE19720312A1 (de) 1997-05-15 1997-05-15 Zubereitung mit erhöhter in vivo Verträglichkeit

Publications (2)

Publication Number Publication Date
AU6600598A AU6600598A (en) 1998-11-19
AU740694B2 true AU740694B2 (en) 2001-11-15

Family

ID=7829495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66005/98A Ceased AU740694B2 (en) 1997-05-15 1998-05-15 Preparation having increased in vivo tolerability

Country Status (17)

Country Link
US (1) US6020315A (2)
EP (1) EP0879605B1 (2)
JP (1) JP4367798B2 (2)
KR (1) KR100547923B1 (2)
CN (1) CN1188134C (2)
AR (1) AR012694A1 (2)
AT (1) ATE333899T1 (2)
AU (1) AU740694B2 (2)
BR (1) BR9801632A (2)
CA (1) CA2237450A1 (2)
CZ (1) CZ149398A3 (2)
DE (2) DE19720312A1 (2)
HU (1) HUP9801087A3 (2)
ID (1) ID20283A (2)
PL (1) PL193478B1 (2)
RU (1) RU2234322C2 (2)
TR (1) TR199800848A3 (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026726A1 (en) * 1995-02-28 1996-09-06 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
CN1159012C (zh) * 1997-08-26 2004-07-28 阿旺蒂斯制药公司 用于组合哌啶子基烷醇-减充血剂的药物组合物
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
BR0008379A (pt) 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB2355007A (en) * 1999-10-08 2001-04-11 Michael Francis Holick Tamoxifen analogue glycosides and use thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
PL363363A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
BR0207487A (pt) 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA03010909A (es) 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
AU2002320964B2 (en) * 2001-08-14 2008-03-13 Valderm Aps Treatment of hyperproliferative conditions of body surfaces
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
BRPI0314133A8 (pt) 2002-09-23 2017-09-19 Bristol Myers Squibb Co Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) * 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
EP2114157B1 (en) * 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
WO2013026454A1 (en) * 2011-08-22 2013-02-28 Valderm Aps Treatment of clinical conditions with anthracyclines
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540859A1 (en) * 1987-08-04 1993-05-12 Bristol-Myers Squibb Company Anthracycline prodrugs
EP0751144A1 (en) * 1995-06-27 1997-01-02 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
DK0795334T3 (da) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540859A1 (en) * 1987-08-04 1993-05-12 Bristol-Myers Squibb Company Anthracycline prodrugs
EP0751144A1 (en) * 1995-06-27 1997-01-02 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOSSLET ETAL, CANCER RESEARCH, VOL54, NO7 (1994) *

Also Published As

Publication number Publication date
CA2237450A1 (en) 1998-11-15
JP4367798B2 (ja) 2009-11-18
HU9801087D0 (en) 1998-07-28
KR100547923B1 (ko) 2006-04-12
CN1199613A (zh) 1998-11-25
KR19980087239A (ko) 1998-12-05
PL193478B1 (pl) 2007-02-28
AU6600598A (en) 1998-11-19
AR012694A1 (es) 2000-11-08
HUP9801087A2 (hu) 1998-12-28
EP0879605A3 (de) 1998-12-02
DE59813653D1 (de) 2006-09-07
CZ149398A3 (cs) 1998-12-16
HUP9801087A3 (en) 1999-05-28
RU2234322C2 (ru) 2004-08-20
DE19720312A1 (de) 1998-11-19
PL326336A1 (en) 1998-11-23
TR199800848A2 (xx) 1998-12-21
US6020315A (en) 2000-02-01
TR199800848A3 (tr) 1998-12-21
BR9801632A (pt) 1999-06-29
ATE333899T1 (de) 2006-08-15
EP0879605A2 (de) 1998-11-25
EP0879605B1 (de) 2006-07-26
ID20283A (id) 1998-11-19
JPH1129497A (ja) 1999-02-02
CN1188134C (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
AU740694B2 (en) Preparation having increased in vivo tolerability
EP0595133B1 (de) Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0795334B1 (de) Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
US8357506B2 (en) Method of identifying improved conjugates of biologically active compounds
HK1255308A1 (zh) 用於治疗由psma表达细胞引起的疾病的共轭物
US20050171342A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US20030073640A1 (en) Novel compositions for the delivery of negatively charged molecules
RU98109154A (ru) Препарат с улучшенной переносимостью in vivo
Colombo et al. Toxicological testing of cytotoxic drugs
KR20070084211A (ko) 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
US8232254B2 (en) Colchicine neoglycosides and methods for their synthesis and use
MXPA02006251A (es) Composiciones y metodos para l-nucleosidos, l-nucleotidos y sus analogos.
AU2001260227A1 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
MXPA98003847A (en) Prepared with in vivo increment compatibility
Hoffmann et al. Structure-activity relationship of anthracyclines in vitro
RU2809635C1 (ru) Конъюгаты монометил ауристатина е с лигандами асиалогликопротеинового рецептора для направленного транспорта в опухолевые клетки печени
Hadjiolov et al. Proline dithiocarbamate inhibits N-nitrosodiethylamine induced liver carcinogenesis
Mathé et al. Second-Generation Anthracyclines
Yagoda Cytotoxic Chemotherapy Phase II Trials Between 1983 and 1990 for Advanced Renal Cell Carcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)